A Study of Quetiapine: Efficacy and Tolerability in Psychotic Adolescents

Shaw, Jon A.; Lewis, John E.; Pascal, Shlomo; Sharma, Rakesh; Rodriguez, Rosemarie; Guillen, Ramiro; Pupo-Guillen, Marilyn

doi:10.1089/104454601317261591

Cited by 96 publications

(59 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results relative to free-thyroid hormone (FT4) reduction are in the line with previous reports in adult [3] and adolescent populations [10,26,27,36] using similar antipsychotic doses and treatment times. Treatment with quetiapine was related to a significant decrease in FT4.…”

Section: Discussionsupporting

confidence: 92%

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

Arango

Robles

Parellada

et al. 2009

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

Objective: To compare the efficacy, safety, and tolerability of olanzapine and quetiapine in adolescents with first episode psychosis. Method: Fifty adolescents (age 16 ± 1.25) with a first episode of psychosis were randomized to quetiapine or olanzapine in a 6-month open label study. Efficacy and side effect scales, as well as vital signs and laboratory data were recorded at baseline, 7, 15, 30, 90, and 180 days (end of study). Results: Out of the total sample included in the study, 32 patients completed the trial (quetiapine n = 16, olanzapine n = 16). Patients in both treatment groups had a significant reduction in all clinical scales with the exception of the negative scale of the Positive and Negative Symptom Scale (PANSS) for olanzapine and the general psychopathology scale of the PANSS for quetiapine. The only difference between treatment arms on the clinical scales was observed on the patients' strength and difficulties questionnaire (SDQ) scale, with greater improvement for olanzapine. Patients on olanzapine gained 15.5 kg and patients on quetiapine gained 5.5 kg. Conclusion: Olanzapine and quetiapine reduced psychotic symptoms in this adolescent sample. Patients on olanzapine gained significantly more weight. Side effects with both drugs seemed to be more prevalent than those reported in adult studies

show abstract

Section: Discussionsupporting

confidence: 92%

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

Arango

Robles

Parellada

et al. 2009

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

show abstract

“…Treatment with quetiapine was associated with minimal adverse events, which is consistent with the majority of quetiapine studies supporting its safety and tolerability, including low incidence of EPS (McConville et al, 2000) and hyperprolactinemia (Shaw et al, 2001). Sedation was the most common adverse event observed in the current study, and has been consistently reported in the literature (Shaw et al, 2001).…”

Section: Discussionsupporting

confidence: 87%

“…Sedation was the most common adverse event observed in the current study, and has been consistently reported in the literature (Shaw et al, 2001). However, the degree to which sedation occurs does not appear to interfere with drug therapy as it is often temporary and rarely requires medication discontinuation (Findling, 2002).…”

Section: Discussionsupporting

confidence: 55%

“…The use of quetiapine in typically developing children and adolescents has been growing because of its favorable side effect profile (Arvanitis & Miller, 1997;McConville et al, 2000;Shaw et al, 2001), and a recent study reported on the use of this medication in six children and adults with autism (Martin, Koenig, Scahill, & Bregman, 1999). The objective of the current study was to assess the effectiveness and tolerability of quetiapine in children and adolescents with PDD via a retrospective chart review.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders

Hardan

Jou

Handen

2005

J Autism Dev Disord

View full text Add to dashboard Cite

A retrospective study was conducted in a clinic specialized in treating individuals with developmental disabilities to examine the effectiveness and tolerability of quetiapine in children and adolescents with pervasive developmental disorders. Ten consecutive outpatients (age = 12.0 +/- 5.1 years) treated with quetiapine (dose = 477 +/- 212 mg, duration = 22.0 +/- 10.1 weeks) were identified and six were judged to be responders based on impressions from chart review and Conners Parent Scale (CPS). Improvements were observed in the conduct, inattention, and hyperactivity subscales of the CPS. Adverse events were mild with sedation being the most common, and no patient required treatment termination. Quetiapine may be beneficial in children and adolescents with pervasive developmental disorders, however open-label and double-blind, placebo-controlled studies are warranted.

show abstract

“…However, an 8-week study by Shaw et al [50]; two 6-week, prospective, comparative studies by Atmaca et al [51,52]; and case reports from Meyer [53] and Domon and Cargile [54] have suggested that quetiapine may share with other benzodiazepine-derived atypical antipsychotics some propensity to elevate serum triglycerides levels. In the 8-week bipolar depression clinical trials, the proportions of quetiapine-treated patients (300 and 600 mg/d) who showed fasting triglyceride elevation ( 200 mg/d) compared with those receiving placebo were 14% and 9%, respectively [55].…”

Section: Quetiapinementioning

confidence: 99%

Weight gain and metabolic issues of medicines used for bipolar disorder

Fagiolini

Chengappa²

2007

Curr Psychiatry Rep

View full text Add to dashboard Cite

Patients with bipolar disorder are at high risk of gaining weight and developing metabolic illnesses, and pharmacologic treatment for the disorder may significantly increase this risk. This paper reviews the literature on the metabolic consequences of the medications used in bipolar disorder and describes the possible strategies to prevent, monitor, and treat the common metabolic illnesses that patients with bipolar disorder may develop during treatment.

show abstract

A Study of Quetiapine: Efficacy and Tolerability in Psychotic Adolescents

Abstract: Quetiapine is suggested to be effective treatment of youths with psychotic disorders and to have a favorable side-effect profile.

Cited by 96 publications

References 2 publications

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders

Weight gain and metabolic issues of medicines used for bipolar disorder

Contact Info

Product

Resources

About